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ABSTRACT 30 
Bioluminescence imaging (BLI) is ubiquitous in scientific research for the sensitive tracking 31 
of biological processes in small animal models. However, due to the attenuation of visible 32 
light by tissue, and the limited set of near-infrared bioluminescent enzymes, BLI is largely 33 
restricted to monitoring single processes in vivo. Here we show, that by combining stabilised 34 
colour mutants of firefly luciferase (FLuc) with the luciferin (LH2) analogue infraluciferin 35 
(iLH2), near-infrared dual BLI can be achievedin vivo. The X-ray crystal structure of FLuc 36 
with a high-energy intermediate analogue, 5’-O-[N-(dehydroinfraluciferyl)sulfamoyl] 37 
adenosine (iDLSA) provides insight into the FLuc-iLH2 reaction leading to near-infrared light 38 
emission. The spectral characterisation and unmixing validation studies reported here 39 
established that iLH2 is superior to LH2 for the spectral unmixing of bioluminescent signals in 40 
vivo; which led to this novel near-infrared dual BLI system being applied to monitor both 41 
tumour burden and CAR T cell therapy within a systemically induced mouse tumour model. 42 
 43 
 44 
 45 
 46 
 47 
 48 
 49 
 50 
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INTRODUCTION 52 
Bioluminescence imaging (BLI) is used extensively for the sensitive, longitudinal and high-53 
throughput monitoring of biological processes in vivo 
1,2,3,4, 5
. Bioluminescence light emission 54 
is produced through the catalysis of a small molecule substrate, most commonly D-luciferin 55 
(D-LH2), by a luciferase enzyme. The mutagenesis of bioluminescent enzymes has improved 56 
the sensitivity and accuracy of BLI in small animals 
6,7
. However, despite its widespread use 57 
in scientific research, BLI is still largely restricted to tracking a single parameter in vivo. The 58 
ability to discretely monitor two biological parameters (dual-BLI) simultaneously within a 59 
single animal is highly desirable 
1
 with potential uses ranging from the monitoring of tumour 60 
burden alongside cellular therapy, to the visualisation of dynamic biological processes such 61 
as protein-protein interactions 
8
. 62 
 63 
Previous approaches to dual-BLI have been disappointing. The use of multiple 64 
bioluminescent proteins which catalyse different substrates is the most frequently used 65 
method but suffers from a number of limitations. Sequential substrate administration is 66 
normally required, in addition this method commonly employs a combination of a 67 
coelenterazine and a D-LH2 utilising luciferase (with the blue emission from the former being 68 
heavily absorbed compared to the yellow-green emission from the latter) 
9,10
. Differences in 69 
biodistribution and reaction kinetics of two substrates can make image co-registration and 70 
interpretation difficult. The development of orthogonal luciferase-luciferin pairs has solved 71 
some of these limitations but this approach still requires multiple substrate administrations 
11
. 72 
 73 
An ideal dual-BLI approach would use two spectrally distinct bioluminescent proteins 74 
utilising a single substrate followed by spectral unmixing of the signal.  However, this 75 
approach is not currently feasible using LH2. Although luciferases can be mutated to alter the 76 
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colour of their emission, a limit appears to have been reached for mutational colour 77 
modulation of firefly and related luciferases. The most red-shifted of these enzymes have 78 
maximal peak emissions between 610 and 620nm 
6
. This is insufficient for dual BLI in vivo. 79 
Due to the differential attenuation of light by biological tissue spectral unmixing of a red-80 
shifted luciferase paired with a standard or green-shifted enzyme is challenging, especially in 81 
deeper tissue models 
12
. Shifting the emission of both enzymes into the near infrared must be 82 
achieved to allow adequate unmixing. To further red-shift peak emission we and others have 83 
turned to chemical modification of the D-luciferin (LH2) substrate 
13
. We recently described 84 
the LH2 analogue infraluciferin (iLH2) which has a luciferase dependent red-shifted peak 85 
emission of up to 706nm 
14
 (Figure 1a). We hypothesized that combining colour modulation 86 
of bioluminescence through mutagenesis of the FLuc protein along with red-shifting 87 
bioluminescence by chemical modification of LH2 would allow dual-BLI, an approach that 88 
has not been described previously. 89 
 90 
In this work, we explored the possible structural interactions in the enzyme that may account 91 
for the near infrared emission of iLH2 and its application to dual-BLI in vivo. First, the X-ray 92 
crystal structure of FLuc in complex with a high-energy intermediate analogue, 5’-O-[(N-93 
dehydroinfraluciferyl)-sulfamoyl] adenosine (iDLSA) was determined to provide insight into 94 
the FLuc-iLH2 light-emitting reaction. Next, we selected a pair of stabilized colour-shifted 95 
FLuc mutants, which emit with a 20nm separation in peak emission wavelength with iLH2 in 96 
the near infrared. We demonstrated the ability to spectrally unmix these two biological 97 
signals in vivo at depth using iLH2. Finally, we show a proof-of-concept of utility using this 98 
novel dual imaging technique to longitudinally monitor both tumour burden and chimeric 99 
antigen receptor (CAR) T cell therapy within a single animal model.  100 
  101 
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RESULTS 102 
Crystal structure of firefly luciferase in complex with a iLH2 analogue 103 
To help understand the red shift in bioluminescence emission from FLuc that is observed in 104 
its reaction with iLH2, the X-ray crystal structure of FLuc in complex with iDLSA was 105 
resolved and is shown in Figure 1b (PDB ID: 6HPS). Data collection and refinement 106 
statistics (molecular replacement); and data collection, phasing and refinement statistics for 107 
mad (semet) structures can be found in Figure 1 -Figure supplement 1. iDLSA captures 108 
FLuc in the adenylation step of the light emitting reaction (
1
H and 
13
C data spectra synthetic 109 
chemical compounds can be found in Figure 1 – Figure supplement 2). The conformation 110 
of the iLH2 heterocyclic rings with respect to the alkene, as drawn in Figure 1a, is confirmed 111 
to be as predicted by computational studies and is the most likely conformation of the light 112 
emitting form 
15
. This newly crystallised FLuc structure was aligned with the reported 113 
structure of FLuc with 5’-O-[(N-dehydroluciferyl)-sulfamoyl] adenosine (DLSA) (PDB ID: 114 
4G36) 
16
. The structures show good alignment to each other, however there is evidence of a 115 
more open active site supported by a reduction in root-mean-squared (RMSD) score when 116 
aligned based on just the N-terminal domain of FLuc rather than the entire structure (RMSD 117 
= 0.688 and 0.783 respectively) (Figure 1c).  118 
 119 
 120 
 121 
 122 
 123 
 124 
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 125 
Figure 1: Crystal structure of Firefly luciferase in complex with a iLH2 analogue 126 
a) Chemical structures of native D-Luciferin (LH2) and the LH2 analogue infraluciferin (iLH2). 127 
b) The crystal structure of Firefly luciferase (FLuc) in complex with the infraluciferyl-adenylate 128 
analogue 5’-O-[(N-dehydroinfraluciferyl)-sulfamoyl] adenosine (iDLSA) resolved to a 3.2 Å 129 
resolution (PDB ID: 6HPS). 130 
c) The structure of FLuc in complex with the iLH2  analogue iDLSA aligned to the reported 131 
structure of FLuc in complex with the LH2 analogue 5’-O-[(N-dehydroluciferyl)-sulfamoyl] 132 
adenosine (DLSA) (PDB ID: 4G36) 16 based on the FLuc N-terminal domain (residues 1-133 
436). The structure of FLuc in complex with iLH2 is shown in red, and the structure of FLuc 134 
in complex with LH2 is shown in orange. 135 
d) The structure of FLuc in complex with luciferin analogue DLSA (PDB ID: 4G36) (orange) 136 
and the infra-luciferin analogue iDLSA (red). Those residues within 4 Å of the substrate in 137 
each structure are highlighted in blue.  138 
e) The table lists all residues within 4 Å of the both substrates, with those in orange or red only 139 
being found within 4 Å of DLSA and iDLSA respectively. 140 
f) Highlights the same 7 active site residues for both the aligned structures, with FLuc iLH2 141 
residues in blue and FLuc LH2 residues in green.  142 
All analysis performed in PyMOL software (Schrodinger).  143 
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Figure 1 - Figure supplement 1 provides data tables for data collection and refinement 144 
statistics (molecular replacement); and data collection, phasing and refinement statistics for 145 
mad (semet) structures.  146 
Figure 1 - Figure supplement 2 provides 
1
H and 
13
C data for synthetic chemical compounds. 147 
 148 
All FLuc residues in close proximity (4 Å) to DLSA were also found to be within the same 149 
distance to iDLSA, with the exception of Arg437, > 4 Å away from iDLSA (Figure 1d and 150 
e). We noted that despite differences in the conformation of iDLSA compared to DLSA in 151 
both 4G36 and L. cruciata 2D1S
 17
 structures, the positions of the phenolic groups are quite 152 
similar (~0.5 Å).  The altered position of the benzothiazole ring and the greater size of 153 
iDLSA may be the cause of a series of small active site changes that affect residues Glu311, 154 
Arg337, Asn338, Gly339, and Thr343 resulting in a total of 6 differences in H-bonding 155 
interactions. When specific residues implicated in the light emitting reaction 
16
 were 156 
measured between the two structures differences ranged from 0.7 – 1.6 Å; with the biggest 157 
divergence being Lys529 (found in the C-terminal cap) which had a 2.4 Å difference in the 158 
nitrogen residue found in the side chain of the amino acid (Figure 1f). The resulting increase 159 
in active site polarity due to the rotation of the C-terminal cap, if maintained during the light 160 
emitting conformation, could contribute to the red-shift in light emission 
17
, in addition to the 161 
increased π-conjugation through the chemical structure of the emitter. This X-ray structure 162 
will help the future design of more efficient FLuc-iLH2 pairs. 163 
 164 
Spectral unmixing of firefly luciferase mutants in vitro 165 
A range of colour-shifted, thermo- and pH stable FLuc mutants
 
were spectrally characterised 166 
in vitro with a comparative selection of LH2 analogues proven to red-shift bioluminescence 167 
emission (CycLuc1
18
, Aka-Lumine-HCL
19
 and iLH2 
14
). Two new luciferins NH2-NpLH2 and 168 
OH- NpLH2  have also been shown to have near infrared emissions 
20
 but these were reported 169 
too late to include in this study. FLuc mutants were engineered to combine mutations 170 
8 
 
reported to provide superior stability 
21
 and colour-shifting capability 
22
 (stabilising and 171 
colour shifting FLuc mutations are detailed in materials and methods). The Raji B 172 
lymphoma cell line engineered to express a FLuc mutant were spectrally imaged after 173 
addition of each substrate. These cell lines were subsequently used for all in vitro and in vivo 174 
testing. Both CycLuc1 and Aka-Lumine-HCL showed a consistent red-shift in peak 175 
bioluminescence emission wavelength to ~600nm and ~660nm respectively for all FLuc 176 
mutants, making these substrates unsuitable for dual colour BLI (Figure 2 – Figure 177 
supplement 1). The data confirmed that with LH2 both FLuc_natural and FLuc_green have a 178 
peak emission of ~560nm, whilst FLuc_red has a peak emission of ~620nm (Figure 2 – 179 
Figure supplement 1) 
21, 22
. When tested with iLH2 all FLuc mutants were shifted >100nm 180 
into the near infrared but maintained their relative spectral shift [FLuc_green ~680nm, 181 
FLuc_natural ~700nm and FLuc_red ~720nm (Figure 2 – Figure supplement 1)]. From this 182 
we progressed further with two FLuc mutants, FLuc_green and FLuc_red to explore their 183 
utility for dual-BLI.  184 
 185 
The ability to spectrally unmix FLuc_green and FLuc_red (Figure 2a) in vitro was 186 
investigated by mixing the two FLuc_mutants expressed in the Raji B lymphoma cell line at 187 
various ratios followed by spectral imaging and unmixing with both LH2 and iLH2 (Figure 188 
2b). As would be expected from accurate spectral unmixing, the top wells were classified as 189 
containing mostly FLuc_green signal, which gradually decreased down the plate in line with 190 
the decreasing proportions of FLuc_green expressing cells, with the bottom wells being 191 
largely classified as FLuc_red signal for both LH2 and iLH2. The percentage unmixed signal 192 
of FLuc_green and FLuc_red was plotted for each ratio of FLuc expressing cells (Figure 2c). 193 
Correlation analysis was performed on this data comparing input cellular proportions with 194 
unmixed signal, giving R
2
 values of 0.9983 and 0.9972 for LH2 and iLH2 respectively. Even 195 
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though all 18 bandpass filters equipped on the IVIS Spectrum were utilised for spectral 196 
unmixing in this in vitro testing, we appreciate that not all potential users of this novel dual 197 
bioluminescence methodology will have access to machines with such a wide selection of 198 
bandpass filters. Therefore, further analysis of our data showed that spectral unmixing could 199 
be achieved with high accuracy just using a subset of filters. For LH2, the use of 3 bandpass 200 
filters (500, 660nm, 820nm) gave an R
2
 value of 0.9958; For iLH2, the use of 3 bandpass 201 
filters (600nm, 700nm, 800nm) gave an R
2
 value of 0.9937. The highest accuracy of spectral 202 
unmixing we could achieve using just 2 filters were R
2 
values of 
 
0.9776 and 0.9775 for LH2 203 
(500nm and 720nm) and iLH2 (600nm and 720nm) respectively. Additionally, an experiment 204 
was carried out where FLuc_green and FLuc_red have been expressed at different levels in 205 
the same cell. Spectral bioluminescence imaging and unmixing has subsequently been 206 
performed to successfully reflect these differing expression levels with both LH2 and iLH2 207 
(Figure 2 – Figure supplement 2). This spectral imaging data shows that both LH2 and iLH2 208 
can be used for dual bioluminescence reporting in vitro. 209 
 210 
 211 
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 212 
Figure 2: Spectral unmixing of Firefly luciferase mutants in vitro 213 
(a) Bioluminescence spectral unmixing of cells expressing colour-shifted Firefly 214 
luciferase (FLuc) mutants, for both in vitro assays and in vivo animal models, 215 
requires spectral bioluminescence imaging through a series of bandpass filters. 216 
Bioluminescence spectral imaging acquires spectral data, which can then be 217 
deconvoluted into its separate components. As depicted, spectral unmixing in vivo is 218 
significantly more challenging due to attenuation of bioluminescent signal that does 219 
not fall within the bio-optical window. 220 
(b) FLuc colour mutants FLuc_green and FLuc_red expressed in the B lymphoma Raji 221 
cell line were mixed in various proportions (0-100% of the total population). After 222 
addition of either D-luciferin (LH2) or infraluciferin (iLH2) plates were spectrally 223 
imaged using the IVIS Spectrum (Perkin Elmer).Unmixed green and unmixed red 224 
output images produced from library spectral unmixing using Living Image software 225 
(Perkin Elmer) for both substrates. 226 
(c) Percentage unmixed signal of FLuc_green and FLuc_red for each ratio of FLuc 227 
expressing cells tested when imaged with LH2 and iLH2. Signal adjusted to 100% 228 
populations. Mean and standard deviation plotted (n=6 for both LH2 and iLH2). 229 
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Figure 2 – Figure supplement 1 gives the spectra of x11 FLuc mutants FLuc_natural, 230 
FLuc_green and FLuc_red with LH2 analogues (a) LH2, b) iLH2, c) CycLuc1 and d) Aka-231 
Lumine-HCL) in vitro, alongside the chemical structure of CycLuc1 and Aka-Lumine-HCL 232 
below the corresponding spectra). Spectra normalised to peak emission for each FLuc 233 
mutant with each substrate. Each point on the x-axis gives the midpoint of the 20nm band 234 
pass filter used in spectral imaging.  235 
Figure 2 – Figure supplement 2 whether FLuc_green and FLuc_red could be successfully 236 
spectrally unmixed when expressed in the same cell was also explored. The mammalian B 237 
Lymphoma Raji cell line was transduced with FLuc_green and FLuc_red, which was then 238 
sorted by flow cytometry using co-expressed marker genes to get cell populations with 239 
differing expression levels of the two luciferases enzymes.  240 
(a) The normalised median fluorescence intensity (MFI) of FLuc_green and FLuc_red 241 
for each cellular population  242 
(b) Differing combinations of low and high expression levels of FLuc_green and 243 
FLuc_red could be detemined using spectral bioluminescence imaging and spectral 244 
unmixing with both LH2 and iLH2. 245 
 246 
Spectral characterisation of firefly luciferase mutants with LH2 and iLH2 in vivo 247 
To investigate the use of FLuc_green and FLuc_red with LH2 and iLH2 for in vivo dual BLI 248 
three NOD scid gamma (NSG) tumour models, representing increasing tissue depth 249 
(subcutaneous, systemic and intracranial), were established with the Raji B lymphoma cell 250 
line expressing either FLuc_green or FLuc_red (as described for in vitro experiments). All 251 
tumour models were then spectrally imaged with both LH2 and iLH2 (Figure 3, Figure 3 – 252 
Figure supplement 1 and Figure 3 – Figure supplement 2) to obtain the normalised 253 
spectra and average radiance of each FLuc mutant with both luciferins in all three in vivo 254 
models (Figure 4). The normalised bioluminescence spectra for every mouse in each model 255 
when imaged with LH2 is shown, with the total radiance for each mouse plotted to the right of 256 
the spectral plot (Figure 4 a-c). The data shows that when imaged with LH2 both FLuc_green 257 
and FLuc_red had an average peak emission between 610-630nm; meaning the peak 258 
emission for FLuc_red is maintained as in vitro whereas the peak emission of FLuc_green is 259 
red shifted by ~60nm in vivo. FLuc_green also exhibited a bimodal spectral distortion, with a 260 
minor peak at ~560nm. In contrast to LH2, FLuc_green and FLuc_red had a ~20nm 261 
12 
 
separation of average peak emissions in all 3 animal models with iLH2 (FLuc_green ~700nm 262 
and FLuc_red ~720nm) (Figure 4 d-f).  263 
 264 
 265 
 266 
 267 
 268 
 269 
 270 
 271 
 272 
 273 
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 274 
Figure 3: Bioluminescent images of FLuc mutants with iLH2 in vivo 275 
A representative selection of filter images from mice engrafted with the Raji B lymphoma cell 276 
line expressing either Fluc_green or Fluc_red for each of the in vivo tumour models when 277 
imaged with iLH2 a) subcutaneous b) systemic and c) intracranial (bandpass filters not 278 
shown are 600nm, 640nm, 680nm, 720nm, 760nm, 800nm).  279 
Figure 3 – Figure supplement 1 gives a representative example of all filter images for 280 
FLuc_green and FLuc_red acquired in each in vivo model after administration of iLH2. 281 
Figure 3 – Figure supplement 2 gives a representative example of all filter images for 282 
FLuc_green and FLuc_red acquired in each in vivo model after administration of LH2 283 
14 
 
 284 
Figure 4: Spectral characterisation of FLuc mutants with LH2 and iLH2 in vivo 285 
The normalised spectra, and a plot of average radiance, for each FLuc mutant when 286 
expressed in the Raji B lymphoma cell line engrafted in each tumour model when imaged 287 
with LH2 is shown, a) subcutaneous b) systemic and c) intracranial, and when the same 288 
animals were imaged with iLH2 is shown, d) subcutaneous e) systemic and f) intracranial. 289 
Subcutaneous (n=9), systemic (n=10), intracranial (n=7). T test used to establish statistical 290 
significance comparing average radiance values (systemic model when imaged with LH2 p = 291 
0.0224). 292 
 293 
 294 
 295 
 296 
 297 
 298 
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In addition to the separation of peak emission wavelengths when imaged with iLH2 in vivo, 299 
the relative intensities of FLuc_green and FLuc_red were more comparable when imaged 300 
with iLH2 than with LH2; With LH2  FLuc_red had an average radiance that was 42 301 
(subcutaneous), 4.12 (systemic) and 7.28 (intracranial) times brighter than FLuc_green 302 
(Figure 4 a-c). Whereas, when imaged with iLH2 the average radiance between FLuc_green 303 
and FLuc_red was 1.38 (subcutaneous), 1.2 (systemic) and 1.51 (intracranial) times different 304 
(Figure 4 d-f). No statistically significant difference in relative intensities between 305 
FLuc_green and FLuc_red was found in tumour models imaged with iLH2 (p = 0.3414, 306 
0.4594 and 0.6153 for the subcutaneous, systemic and intracranial tumour models 307 
respectively, T test). This comparability of relative intensities between FLuc_green and 308 
FLuc_red with iLH2 means that if used as genetic reporters for dual imaging, the dynamic 309 
range of radiance values for both enzymes will be more similar, therefore giving a more 310 
accurate comparison of the processes being monitored.   311 
 312 
Spectral unmixing of firefly luciferase mutants in vivo 313 
To validate the ability to spectrally unmix FLuc_green and FLuc_red in vivo with iLH2 a 314 
systemic Raji tumour model was established. Raji cell lines expressing the FLuc mutants 315 
were mixed in the following ratios: 90:10, 75:25 and 50:50 for FLuc_green: FLuc_red and 316 
vice versa. After spectral BLI with both substrates, animals were sacrificed and the bone 317 
marrow was extracted for flow cytometry analysis to confirm the proportions of engrafted 318 
Raji FLuc populations (representative examples of flow cytometry plots can be found in 319 
Figure 5 – Figure supplement 1). Spectral unmixing was performed using Living Image 320 
(Perkin Elmer) by creating library spectra of FLuc_green and FLuc_red with both LH2 and 321 
iLH2, established from the pure expressing populations obtained during in vivo spectral 322 
characterisation (Figure 4). Output images with both LH2 (Figure 5a) and iLH2 (Figure 5b) 323 
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were generated for FLuc_green and FLuc_red, as well as a composite image for each 324 
substrate.  325 
 326 
 327 
Figure 5: Spectral unmixing of Firefly luciferase mutants in vivo 328 
The Raji B lymphoma cell line expressing either FLuc_green or Fluc_red, were mixed in 329 
various proportions and engrafted in a systemic in vivo model. Cell mixtures ranged from 330 
90:10 to 10:90 Fluc_green to Fluc_red, and each imaging session included one mouse 331 
engrafted with each mixture. Animals were spectrally imaged with D-Luciferin (LH2) and 332 
infraluciferin (iLH2) using the IVIS spectrum (Perkin Elmer) in separate imaging sessions. 333 
a) An example of the unmixed Fluc_green, umixed Fluc_red and composite output 334 
images when imaged with LH2 and b) iLH2. Percentage of unmixed Fluc_green and 335 
Fluc_red signal for each cell mixture when imaged with c) LH2  d) iLH2, and e) 336 
extracted bone marrow samples when analysed by flow cytometry (n = 4 per dilution 337 
condition). 338 
Figure 5 – Figure supplement 1 gives representative flow cytometry plots showing gating of 339 
extracted bone marrow sample from a) an FLuc mutant Raji tumour model and from b) a 340 
control mouse. c)alsorepresentative flow cytometry plots from a mouse engrafted with each 341 
different mixture of mutant FLuc Raji cells (ratio given is Fluc_green: Fluc_red).  342 
 343 
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 344 
 345 
 346 
The percentage signal unmixed as FLuc_green and FLuc_red with both LH2 (Figure 5c) and 347 
iLH2 (Figure 5d) was determined and correlated to the percentage population of each 348 
FLuc_mutant within the Raji cell population taken from extracted bone marrow samples and 349 
analysed using flow cytometry (Figure 5e). A correlation of 0.99 was found with iLH2 (R
2 
350 
value, SD=0.01). LH2 had a correlation of 0.89 (R
2
 value, SD =0.06), which was significantly 351 
different from the R
2 
values obtained by flow cytometry (p < 0.0001, ONE-Way ANOVA 352 
with post hoc Tukey test). No significant difference was found between R
2 
values determined 353 
by flow cytometry and unmixed bioluminescence signal using iLH2. Additionally, significant 354 
differences were found between the percentage unmixed signal using LH2 and cellular 355 
proportions determined by flow cytometry, with p values of <0.0001, 0.003, 0.0042 and 356 
0.0056 for the 90%, 75%, 50% and 25% FLuc_green conditions respectively. No significant 357 
difference was found between percentage unmixed signal using iLH2 and cellular proportions 358 
determined by flow cytometry, except for the 90% FLuc_green condition (p = 0.0257). 359 
Therefore, iLH2 is superior to LH2 for in vivo dual reporting applications. 360 
 361 
Application of dual bioluminescence imaging using infraluciferin 362 
The characterised and validated in vivo dual BLI system using FLuc mutants in combination 363 
with iLH2 was then applied to track tumour burden and CAR T cell therapy within the same 364 
animal model. A Raji B lymphoma tumour cell line expressing FLuc_green was used, and 365 
healthy human donor T cells were engineered to express CD19 CAR and FLuc_red linked via 366 
a 2A peptide. Tumour cells were first systemically engrafted, followed by administration of 367 
18 
 
CAR T cells 8 days later. A control animal received tumour only. Spectral BLI using iLH2 368 
was then performed at 3, 4 and 6 days post CAR T cell administration on the IVIS Spectrum. 369 
 370 
Output images for the unmixed FLuc_green and FLuc_red signal, as well as the composite of 371 
the two unmixed images, for day 6 post CAR T cell administration were generated (Figure 372 
6a). The radiance values from the unmixed FLuc_green and FLuc_red images for both 373 
tumour control and treatment (tumour + CAR T cells) at 3, 4 and 6 days post CAR T cell 374 
treatment were determined (Figure 6b). As would be expected, the tumour only control 375 
showed consistently high levels of FLuc_green signal which increased overtime compared to 376 
FLuc_red, which is likely due to the close proximity of Fluc_red photons emitted by the 377 
neighbouring treatment mouse.  However, the CAR T cell treatment mice initially had a 378 
higher proportion of FLuc_green signal, which was then surpassed by FLuc_red by the final 379 
imaging. This represents the homing of CAR T cells expressing FLuc_red to the FLuc_green 380 
expressing Raji B lymphoma tumour, followed by the expansion of the CAR T cells and the 381 
reduction in the tumour growth in the treatment mice.  382 
 383 
 384 
 385 
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 386 
 387 
 388 
Figure 6: Dual bioluminescence imaging of CAR T cell therapy using infraluciferin 389 
Mice were engrafted with the Raji B lymphoma tumour cell line expressing Fluc_green, and 390 
were subsequently treated with healthy human donor T cells engineered to express CD19 391 
CAR and FLuc_red (except the tumour only control). Animals were then spectrally imaged 392 
after administration of iLH2 using the IVIS spectrum (Perkin Elmer).  393 
(a) The unmixed Fluc_green images, representing tumour burden, and unmixed Fluc_red 394 
images, representing CAR T cell homing, and the composite image are shown for day 6 395 
post CAR T cell treatment.  396 
(b) The average radiance of signal classified as Fluc_green and Fluc_red is plotted for days 397 
3, 4 and 6 post CAR T cell administration for the tumour only control and treatment 398 
(tumour + CAR T cells) animals. 3 mice were randomly selected to receive CAR T cell 399 
therapy after engraftment was confirmed.  Mean and standard deviation plotted. 400 
Radiance values from each femur are treated separately (tumour only = 2, treatment =6). 401 
 402 
 403 
 404 
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DISCUSSION 405 
 406 
Small animal dual (or multi-parameter) bioluminescence is highly desirable. Currently, most 407 
dual BLI has been achieved with two luciferases each utilising a different substrate, one of 408 
which is normally the auto luminescent coelenterazine 
9
. A simpler approach would be to use 409 
a single LH2 substrate and two firefly (or related) luciferases which emit at different 410 
wavelengths. This in theory has advantages of higher quantum yield and a more favourable 411 
substrate. Such an approach has been attempted: for instance Mezzanotte et al tested dual BLI 412 
in vivo using  LH2 with the green luciferase (CBG99) with the red luciferase (Ppy RE8) 
12
. 413 
However, in deeper tissues the shorter wavelength component of green emitting enzyme 414 
emission is heavily attenuated by mammalian tissues leaving an “in vivo spectrum” which is 415 
almost indistinguishable from that of the red luciferase.  416 
 417 
To illustrate this, and as a control for subsequent experiments, we attempted dual BLI using a 418 
pair of stabilized firefly luciferases, which are green / red shifted to 546nm and 610nm 419 
respectively using LH2 as a substrate 
23
. Whilst in vitro the spectra could be easily 420 
distinguished (Figure 2) in vivo the spectral separation between the two FLuc enzymes was 421 
lost due to the differential attenuation of the green enzyme by biological tissue (Figure 4). 422 
An obvious solution is to red-shift both enzymes into the optic window while maintaining an 423 
adequate separation. However, although bioluminescence emission has been successfully red-424 
shifted through mutagenesis of firefly luciferase the structure of the LH2 substrate ultimately 425 
limits this approach. Dual BLI with a single substrate in the near-infrared should be better; 426 
this has been described using BRET based reporters with an coelenterazine derived substrate 427 
24
.  To move bioluminescence into the near infrared modification of the LH2 substrate was 428 
required. Indeed, red-shifted luciferin analogues have been reported. These include CycLuc1 429 
21 
 
and Aka-Lumine, however neither permit variation in emission spectra with different 430 
Luciferase mutants 
18, 19, 7
 (Figure 2). More recently, two Naphthyl luciferins, NH2-NpLH2 431 
and OH-NpLH2, were reported to red shift the in vitro bioluminescence emission of CBR to 432 
664nm and 758nm respectively (emission max 614nm with LH2). Interestingly, NH2-NpLH2 433 
was shown to have an in vitro peak emission of 730nm with an optimised version of CBR 434 
(CBR2). The potential application of CBR and CBR2 with NH2-NpLH2 for dual-BLI in vivo 435 
was not explored; and the reported broad emission spectrum of optCBR2 in live cells is likely 436 
to make any near-infrared dual BLI with NH2-NpLH2 challenging, however this approach 437 
cannot be discounted 
20
. 438 
 439 
We described previously iLH2, which has a near-infrared emission and in contrast to other 440 
LH2 analogues maintains the 6’ hydroxyl benzothiazole group of LH2  that preserves the 441 
colour-shifts of mutant luciferases 
14
. Analysis of the x-ray crystal structure of FLuc in 442 
complex with the iLH2 analogue (iDLSA) revealed that the hydrogen-bonding network, 443 
thought to be critical in stabilizing the phenolate ion of the emitter, is disrupted in the FLuc-444 
iDLSA due to the accommodation of the larger iLH2 substrate 
25
. This enables full charge 445 
delocalization of the phenolate ion, in addition to extended conjugation, resulting in a red-446 
shifted emission as suggested by homology modelling experiments with the recently 447 
described near infrared emitting naphthyl analogue 
20
. Evidence for the disruption of the 448 
network is the absence of a H-bond between Arg337 and Glu311 that is found in the DLSA 449 
structures of FLuc and L. cruciata Luc. This H-bonding interaction has been proposed to be 450 
important for stabilising an active site conformation for green light emission 
26
. In addition, 451 
the resulting increase in active site polarity due to the rotation of the C-terminal cap could 452 
also contribute to the red-shift in light emission 
17
. It must be noted that the crystal structure 453 
reported here has captured FLuc in the adenylation step of the reaction, therefore further 454 
22 
 
computational modelling/crystal structure elucidation would be expected to provide further 455 
information on the light-emitting step of the reaction with iLH2 
15, 17 
. Finally, the more open 456 
adenylation conformation of FLuc -iDLSA may affect the adenylate significantly, altering 457 
light production by decreasing the yield of the electronically excited state emitter and/or the 458 
efficiency in which the emitter produces a photon.  Moreover, small differences in the 459 
binding position of the adenylate seen here, caused by positional changes of key active site 460 
residues could have a similar effect. 461 
 462 
Given that iLH2 preserves the colour modulation of mutant luciferases (in addition to the 463 
100nm red shift), we set about to explore dual-BLI with iLH2. We identified two stabilised 464 
FLuc enzymes with colour shifting mutations: FLuc_green (V241I/G246A/F250S) and 465 
Fluc_red (S284T). Both exhibit a wide separation in peak emission wavelength, and were 466 
also balanced in their relative intensities. We next compared in vitro spectra with in vivo 467 
spectra from luciferase expressing cells implanted subcutaneously, systemically and 468 
intracranially (to approximate superficial, intermediate and deep light source) with both LH2 469 
and iLH2. The near-infrared emission of the FLuc mutants with iLH2 meant spectral 470 
separation was maintained for all animal tumour models. Importantly, the spectra of the two 471 
FLuc mutants remained consistent over tissue depth, meaning this dual BLI system could be 472 
applied to animal models without prior spectral characterisation. This maintenance of spectral 473 
separation, and similarity of relative intensities, between FLuc_green and FLuc_red when 474 
imaged with iLH2 meant this near-infrared bioluminescence system was found to be 475 
significantly better at spectral unmixing in vivo than using LH2. This was demonstrated when 476 
the unmixed bioluminescent signals were correlated with actual cellular populations, 477 
determined by flow cytometry, (R
2 
= 0.99 and 0.89 for iLH2 and LH2 respectively).  478 
 479 
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One potential limitation of this system in its current state is the lower quantum yield of the 480 
FLuc-iLH2 reaction when compared to the FLuc-LH2 reaction, ~2-3 orders of magnitude 481 
dimmer. However, in this study, all mice were successfully spectrally imaged with both LH2 482 
and iLH2, which can be attributed to the sensitivity of the photon counting capabilities of the 483 
CCD cameras fitted in optical imagers 
27
. The crystal structure reported here will be 484 
important for further optimisation of this near-infrared dual BLI system, particularly to 485 
increase the brightness of the current enzymes with iLH2, as well as the discovery of novel 486 
luciferase colour-mutants which could be used for multi-coloured BLI in the near-infrared. 487 
Additionally, the use of this system in combination with luciferases utilising other substrates 488 
for multi-coloured BLI could also be explored, as well as its application to monitoring more 489 
complex processes in animal models 
28
. This work represents an important step forward in 490 
increasing the utility of BLI and opens up the window for multi-coloured BLI in the near-491 
infrared. 492 
 493 
 494 
 495 
 496 
 497 
 498 
 499 
 500 
 501 
 502 
 503 
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 504 
MATERIALS AND METHODS  505 
 506 
Key Resources Table 507 
 508 
Reagent type 
(species) or 
resource 
Designation 
Source or 
reference 
Identifiers 
Additional 
information 
gene (Photinus 
pyralis) 
FLuc this paper N/A 
Amino acid 
changes from 
ref 21 and 23, 
codon 
optimised for 
mammalian 
expression for 
use in this 
paper  
strain, strain 
background (mouse, 
male) 
NSG 
Jax™ mouse 
strain 
(Charles 
River) 
NOD.Cg-
Prkdcscid Il2rgtm1WjI/SzJ 
N/A 
cell line (Human, 
male) 
Raji B 
lymphoma 
ATCC® CCL-
86™ 
N/A 
Mycoplasma 
tested by 
GATC 
(Eurofins 
Genomics) 
antibody 
Anti-human 
CD34-PE 
Biolegend 
Clone 581, RRID 
AB_1731862 
(1:20) 
antibody 
Anti-human 
CD271-APC 
Biolegend 
Clone ME20.4, RRID 
AB_10645515 
(1:20) 
chemical compound, 
dye 
Viability APC 
eFluoro780 
eBioscience N/A (1:1000) 
antibody 
Anti-
mouse/human 
CD11b 
PerCP/Cy5.5 
Biolegend 
Clone M1/70, RRIB 
AB_893232 
(1:20) 
antibody 
Anti-human 
CD19 FITC 
eBioscience 
Clone HIB19, RRID 
AB_10669461 
(1:20) 
antibody 
Anti-human 
CD20 eFLuor 
450 
eBioscience 
Clone 2H7, RRID 
AB_1633384 
(1:20) 
chemical compound, 
drug 
Luciferin 
Regis 
technologies 
N/A N/A 
software, algorithm Living Image Perkin Elmer N/A N/A 
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software, algorithm Prism Graphpad N/A N/A 
software, algorithm Excel Microsoft N/A N/A 
software, algorithm Flow Jo 
Tree Star Inc 
(Oregon, 
USA) 
N/A N/A 
software, algorithm 
PyMOL 
software  Schrodinger 
N/A N/A 
software, algorithm 
CrysalisPro  
Agilent 
Technologies 
N/A N/A 
software, algorithm 
BD 
FACSDIVA 
BD 
biosciences 
N/A N/A 
other         
chemical compound, 
drug 
infraluciferin 
Anderson, 
J.C.; Grounds, 
H.; Jathoul, 
A.P.; Murray, 
J.A.H.; 
Pacman, S.J.; 
Tisi, L. RSC 
Advances 
2017, 7, 3975-
82 
N/A 
Prepared by 
JC Anderson 
laboratory 
chemical compound, 
drug 
iDLSA this paper 
N/A 
Prepared by 
JC Anderson 
laboratory, see 
supplementary 
information. 
chemical compound, 
drug CycLuc1 
Merck 
Millipore 
N/A N/A 
chemical compound, 
drug 
Aka-Lumine-
HCL 
Wako Pure 
Chemical 
Industries 
N/A N/A 
 509 
 510 
Preparation of 5’-o-[(n-dehydroinfraluciferyl)-sulfamoyl] adenosine dehydroinfraluciferin  511 
All manipulations were routinely carried out under an inert (Ar or N2) atmosphere. All 512 
reagents were used as received unless stated. For the purposes of thin layer chromatography 513 
(tlc), Merck silica-aluminium plates were used, with uv light (254 nm) and potassium 514 
permanganate or anisaldehyde for visualisation. For column chromatography Merck 515 
Geduran
®
 Si 60 silica gel was used. Butyl lithium solutions were standardised with diphenyl 516 
acetic acid.  517 
 518 
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Melting points are uncorrected and were recorded on a Griffin melting point machine. 519 
Infrared spectra were recorded using a Bruker Alpha ATR spectrometer. All NMR data was 520 
collected using a Bruker AMX 300 MHz or Bruker AVANCE III 600 MHz as specified. 521 
Reference values for residual solvents were taken as δ = 7.27 (CDCl3), 2.51 (DMSO –d6), 522 
3.30 (MeOD- d4) ppm for 
1H NMR and δ = 77.2 (CDCl3), 39.5 (DMSO –d6), 49.0 (MeOD- 523 
d4) ppm for 
13
C NMR. 
19
F NMR spectra were measured using a Bruker DX300 spectrometer, 524 
referenced to trichlorofluoromethane.
 
Coupling constants (J) are given in Hz and are 525 
uncorrected. Where appropriate COSY and DEPT experiments were carried out to aid 526 
assignments. Mass spectroscopy data was collected on a Micromass LCT Premier XE (ESI) 527 
instrument. Elemental analysis was performed on an Exeter Analytical Inc. CE-440 CHN 528 
analyser. 
 
529 
 530 
6-(β-Methoxyethoxymethylether)benzothiazole (1),32  531 
6-(β-Methoxyethoxymethyl ether)-2-formylbenzothiazole (2),33 532 
1-(4-methoxycarbonylthiazole)methyltriphenylphosphonium chloride
34,35 
533 
2’,3’-O-Isopropylidene-5’-O-sulfamoyladenosine36 were synthesised using procedures 534 
reported in the literature. 535 
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 536 
Figure 7: Synthesis of iDLSA 537 
 538 
6-(β-Methoxyethoxymethoxy)-2-(2-(4-methoxycarbonylthiazol-2-yl)ethenyl) benzothiazole 539 
(3). A suspension of aldehyde 2 (200 mg, 0.748 mmol) and 1-(4-540 
methoxycarbonylthiazole)methyltriphenylphosphonium chloride (680 mg, 1.50 mmol) in 541 
DMF (3.5 mL) was cooled to 0 °C and treated with K2CO3 (348 mg, 2.52 mmol). The 542 
resultant solution was allowed to warm to rt and stirred for 16 h. After this time H2O (40 mL) 543 
was added and the solution extracted using EtOAc (2 × 40 mL). The organics were combined 544 
and washed with H2O (40 mL), separated, dried (MgSO4), filtered and concentrated in vacuo. 545 
Purification was achieved using flash column chromatography (60 % Et2O/Hexane) to give 3 546 
as a mixture of cis and trans isomers (163 mg, 54 %). 547 
 548 
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Cis: Rf = 0.52 (60 % EtOAc/Hexane); 
1
H NMR (600 MHz, CDCl3) δ 3.39 (3H, s, OCH3), 549 
3.58-3.59 (2H, m, OCH2CH2O), 3.86-3.89 (2H, m, OCH2CH2O), 4.00 (3H, s, OCH3),  5.36 550 
(2H, s, OCH2O), 6.96 (1H, d, J = 12.8,  CHC(N)S), 7.25-7.29 (2H, m, ArH, CHC(N)S), 7.62 551 
(1H, d, J = 2.3, ArH), 8.06 (1H, d, J = 8.9, ArH), 8.28 (1H, s, CHS). In CDCl3 solution the 552 
trans isomer was seen to isomerise to the cis isomer. 553 
Trans: A pure sample of trans was by separated by column chromatography to give 3 as a 554 
yellow solid. m.p. 112-115 °C; Rf = 0.48 (60 % EtOAc/Hexane); IR νmax 3101, 2926 (νCH), 555 
2889 (νCH), 2818 (νCH), 1716 (νCO), 1629, 1598, 1556, 1495, 1456, 1333, 1318, 1281, 1239, 556 
1222, 1208, 1162, 1089, 1046, 978 cm
-1
; 
1
H NMR (600 MHz, CDCl3) δ 3.39 (3H, s, OCH3), 557 
3.58-3.59 (2H, m, OCH2CH2O), 3.86-3.88 (2H, m, OCH2CH2O), 4.00 (3H, s, OCH3),  5.35 558 
(2H, s, OCH2O), 7.22 (1H, dd, J = 8.9, 2.4, ArH), 7.59 (1H, d, J = 2.4, ArH), 7.68 (2H, s, 559 
CHC(N)S), 7.92 (1H, d, J = 8.9, ArH), 8.21 (1H, s, CHS); 
13
C NMR (150 MHz, CDCl3) δ 560 
52.8 (CH3), 59.2 (CH3), 68.0 (CH2), 71.7 (CH2), 94.0 (CH2), 107.5 (CH), 117.9 (CH), 124.1 561 
(CH), 128.2 (CH), 128.7 (CH), 136.2 (C), 148.1 (C), 148.9 (C), 156.3 (C), 161.7 (C), 162.9 562 
(C), 165.6 (C); m/z (ESI) 407 (100%, M
+
+H); HRMS C18H19N2O5S2 calcd. 407.0735, found 563 
407.0738. 564 
 565 
(E)-6-(β-Methoxyethoxymethoxy)-2-(2-(4-carboxythiazol-2-yl)ethenyl) benzothiazole (4). A 566 
suspension of 3 (20 mg, 0.049 mmol) in THF (0.75 mL) and H2O (0.37 mL) was treated with 567 
LiOH.H2O (5.0 mg, 0.12 mmol) and stirred for 15 min. After this time H2O (10 mL) and 568 
EtOAc (10 mL) were added and the layers separated. The aqueous layer was acidified with 2 569 
M HCl and extracted using EtOAc (2 × 10 mL), organics dried over MgSO4, filtered and 570 
concentrated in vacuo to give 4 (19 mg, quant.) as a yellow solid. m.p. 175-178 °C; Rf = 0.20 571 
(50 % EtOAc/MeOH); IR νmax 3101 (νOH), 2917 (νCH), 1680 (νCO), 1598, 1554, 1455, 1398, 572 
1320, 1241, 1204, 1160, 1101, 1045, 938 cm
-1
;  
1
H NMR (600 MHz, MeOD-d4) δ 3.33 (3H, 573 
s, OCH3), 3.57-3.58 (2H, m, OCH2CH2O), 3.84-3.85 (2H, m, OCH2CH2O), 5.36 (2H, s, 574 
OCH2O), 7.25 (1H, dd, J = 8.9, 2.4, ArH), 7.69 (1H, d, J = 2.4, ArH), 7.71 (1H, dd, J = 16.1, 575 
0.6, CHC(N)S),  7.73 (1H, d, J = 16.1, CHC(N)S), 7.80 (1H, d, J = 8.9, ArH), 8.43 (1H, s, J 576 
= 7.5, CHS);
 13
C NMR (150 MHz, MeOD-d4) δ 59.1 (CH3), 69.0 (CH2), 72.8 (CH2), 95.0 577 
(CH2), 108.7 (CH), 119.0 (CH), 124.7 (CH), 128.5 (CH), 129.1 (CH), 130.1 (CH), 137.5 (C), 578 
149.8 (C), 150.0 (C), 157.7 (C), 163.8 (C), 164.6 (C), 166.7 (C); m/z (ESI) 393 (100%, 579 
M
+
+H), 300 (9%); HRMS C17H17N2O5S2 calcd. 393.0579, found 393.0581; Anal. Calcd. for 580 
C17H16N2O5S2: C, 52.03; H, 4.11; N, 7.14. Found C, 51.85; H, 4.29; N, 6.71 %. 581 
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 582 
 583 
6-(β-Methoxyethoxymethoxy)-2-(2-(4-pentafluorophenoxycarbonylthiazol-2-yl)ethenyl) 584 
benzothiazole (5). A solution of 4 (30 mg, 0.077 mmol) in pyridine (3.80 mL) was treated 585 
with EDC (18 mg, 0.096 mmol) and pentafluorophenol (18 mg, 0.096 mmol) and stirred at rt 586 
for 16 h. The reaction mixture was concentrated in vacuo. Purification was achieved using 587 
flash column chromatography (30 % Et2O/hexane) to give 5 as a yellow solid (37 mg, 86 %). 588 
m.p. 87-91 °C; Rf = 0.25 (30 % EtOAc/Pet. Ether); IR νmax 2922, 2887, 2835, 1764 (νCO), 589 
1599, 1554, 1486, 1470, 1454, 1321, 1290, 1260, 1242, 1211, 1199, 1180, 1137, 1123, 1100, 590 
1060, 1010, 986 cm
-1
; 
1
H NMR (600 MHz, CDCl3) δ 3.40 (3H, s, OCH3), 3.59-3.60 (2H, m, 591 
OCH2CH2O), 3.87-3.88 (2H, m, OCH2CH2O), 5.36 (2H, s, OCH2O), 7.23 (1H, dd, J = 8.9, 592 
2.4, ArH), 7.60 (1H, d, J = 2.4, ArH), 7.72 (1H, dd, J = 16.2,  0.6, CHC(N)S), 7.74 (1H, d, J 593 
= 16.2, CHC(N)S), 7.94 (1H, d, J = 9.0, ArH), 8.40 (1H, d, J = 0.4, CHS); 
13
C NMR (150 594 
MHz, CDCl3) δ 59.2 (CH3), 68.0 (CH2), 71.7 (CH2), 94.0 (CH2), 107.5 (CH), 117.9 (CH), 595 
124.3 (CH), 124.9 (C), 127.3 (CH), 129.8 (CH), 131.4 (CH), 136.4 (C), 137.3 (C), 139.0 (C), 596 
140.6 (C), 142.2 (C), 144.7 (C), 149.2 (C), 156.4 (C), 156.8 (C), 162.5 (C), 166.6 (C); 
19
F 597 
NMR (CDCl3, 282) δ -150.0 (d, J = 16.9, ArF), -157.14 (app t, J = 19.7, ArF), -161.9 (dd, J = 598 
19.7, 16.9, ArF); m/z (ESI) 559 (100%, M
+
+H); HRMS C23H15F5N2O5S2 calcd. 559.0415, 599 
found 559.0418. 600 
 601 
2’,3’-O-Isopropylidene-5’-O-[N-(6-(β-methoxyethoxymethoxy)-dehydroinfraluciferyl)-602 
sulfamoyl]adenosine (6). A solution of 2’,3’-O-Isopropylidene-5’-O-sulfamoyladenosine (20 603 
mg, 0.052 mmol) in DMF (1.8 mL) was treated with DBU (11 mg, 0.076 mmol) and stirred 604 
at rt for 10 min. A solution of 5 (29 mg, 0.052 mmol) in DMF (0.2 mL) was then added 605 
dropwise. The reaction was stirred at rt for 16 h. After this time pyridine (0.15 mL) was 606 
added and the solution stirred for 4 h. The resultant solution was concentrated in vacuo and 607 
purified using flash column chromatography (5 % MeOH/DCM) to give 6 (30 mg, 76 %) as a 608 
yellow solid. m.p. 164 °C, dec.; Rf = 0.32 (5 % MeOH/DCM); IR νmax 3290 (νOH), 2932 609 
(νCH), 1644 (νCO), 1598, 1552, 1505, 1457, 1418, 1373, 1291, 1250, 1209, 1150, 1103, 1080, 610 
1048, 985 cm
-1
; 
1
H NMR (600 MHz, DMSO-d6) δ 1.34 (3H, s, C(CH3)2), 1.54 (3H, s, 611 
C(CH3)2), 3.21 (3H, s, OCH3), 3.46-3.49 (2H, m, OCH2CH2O), 3.74-3.78 (2H, m, 612 
OCH2CH2O), 4.09 (1H, dd, J = 11.0, 4.9, CH2OS(O)2), 4.12 (1H, dd, J = 11.0, 4.9, 613 
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CH2OS(O)2), 4.42-4.46 (1H, m, OCHCH2), 5.09 (1H, dd, J = 6.1, 2.5, CHCHO), 5.36 (2H, s, 614 
OCH2O), 5.41 (1H, dd, J = 6.1, 2.9, CHCHNO), 6.17 (1H, d, J = 2.9, CHCHNO), 7.22 (1H, 615 
dd, J = 8.9, 2.5, ArH), 7.35 (2H, br, NH2), 7.71 (1H, d, J = 16.1, CHC(N)S), 7.79 (1H, d, J = 616 
16.0, CHC(N)S), 7.79 (1H, d, J = 2.5, ArH), 7.95 (1H, d, J = 8.9, ArH), 8.11 (1H, s, CHS), 617 
8.12 (1H, s, NCH(N)), 8.44 (1H, s, NCH(N)); 
13
C NMR (150 MHz, DMSO-d6) δ 25.2 (CH3), 618 
27.1 (CH3), 58.1 (CH3), 67.3 (CH2), 67.6 (CH2), 71.0 (CH2), 81.6 (CH), 83.5 (CH), 83.9 619 
(CH), 89.3 (CH), 93.3 (CH2), 108.0 (CH), 113.2 (C), 117.4 (CH), 118.8 (C), 123.6 (CH), 620 
125.2 (CH), 126.1 (CH), 128.5 (CH), 136.0 (C), 139.6 (CH), 148.6 (C), 149.0 (C), 152.8 621 
(CH), 155.3 (C), 156.1 (C), 156.8 (C), 162.8 (C), 162.9 (C), 165.0 (C); m/z (ES
+
) 761 (100%, 622 
M
+
+H); HRMS C30H30N8O10S3 calcd. 761.1482, found 761.1486. 623 
 624 
6-Hydroxy-2-(4-1E,3E-(4-ethoxycarbonyl-4,5-dihydrothiazol-2-yl)buta-2,4-625 
dienyl)benzothiazole (iDLSA). A solution of 6 (20 mg, 0.026 mmol) in TFA (0.32 mL) was 626 
stirred at rt for 2 h and then H2O (0.1 mL) added and the solution concentrated in vacuo. 627 
EtOH (2 mL) added and concentrated in vacuo to give the TFA salt of iDLSA (18 mg, 94 %) 628 
as an orange solid. m.p. 68-70 °C; IR νmax 3102 (νOH), 1667 (νCO), 1426, 1132 cm
-1
; 
1
H NMR 629 
(600 MHz, DMSO-d6) δ 4.20-4.25 (2H, m, CHOH, CHOH), 4.53-4.59 (3H, m, CHOC, 630 
CH2OS(O)2), 5.96 (1H, d, J = 5.0, CHCHNO), 7.00 (1H, d, J = 2.4, ArH), 7.42 (1H, d, J = 631 
2.5, ArH), 7.72 (1H, d, J = 15.9, CHC(N)S), 7.84 (1H, d, J = 8.8, ArH), 7.95 (1H, d, J = 15.8, 632 
CHC(N)S), 8.33 (1H, s, CHS), 8.53 (1H, s, NCH(N)), 8.59 (1H, s, NCH(N)). 
13
C NMR too 633 
weak due to poor solubility of compound. MS did not give M+ or meaningful fragment for 634 
accurate mass measurement. 635 
  636 
 
637 
Preparation of the P.pyralis luciferase-5’-o-[(n-dehydroinfraluciferyl)-sulfamoyl] 638 
adenosine dehydroinfraluciferin (FLuc-iDLSA) complex 639 
Approximately 0.6 mg of iDLSA was suspended in 500 µL of crystallization buffer (25 mM 640 
Tris-Cl containing 200 mM AmSO4, 1 mM DTT, 1 mM EDTA) pH 7.85 at 21°C. The 641 
solution was vortexed vigorously and sonicated. Most of the solid was dissolved and the 642 
concentration was determined to be ~1 mM by UV absorbance (using an extinction 643 
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coefficient of 8200 at 372 nm for this buffer and pH). A 20 mg/mL solution of P. 644 
pyralis luciferase (PpyWT that contains the N-terminal peptide GPLGS-) in the same buffer 645 
(500 µL) was mixed gently with the iDLSA at room temperature and then incubated at 15°C 646 
for 20 min. The concentration of iDLSA in the protein-inhibitor mixture was determined by 647 
UV absorbance to be 620 µM, giving an inhibitor:enzyme ratio of ~3:1, at this point the 648 
bioluminescence activity of the mixture was assayed and the enzyme was 85% inhibited. A 649 
small amount of a separate iDLSA solution (available from solubility trials) was added to 650 
bring the inhibitor:enzyme ratio to ~4:1, and based on activity the enzyme was 91% 651 
inhibited. Finally, the protein-inhibitor solution was added to ~0.5 mg of iDLSA and mixed 652 
gently and incubated at 15 °C for 15 min. Based on activity, 99% of the enzyme was 653 
inhibited and based on UV absorbance the inhibitor:enzyme ratio was 5.6:1 (950 µM:170 654 
µM) The protein-inhibitor solution was centrifuged and a very slight amount of inhibitor was 655 
evident.  The supernatant was frozen in liquid nitrogen in ~ 18-50µL aliquots and stored at -656 
80°C. A single aliquot was thawed and the solution remained clear. The pH of this solution at 657 
6°C should be 8.3, pH 8.17 at 10°C, and pH 7.9 at 21°C. 658 
 659 
Crystallisation and refinement of P. pyralis luciferase/dehydroinfraluciferin DLSA 660 
complex 661 
Approximately 0.6 mg of iDLSA was resuspended in 500µL of buffer (25mM Tris-Cl 662 
containing 200mM (NH4)2SO4, 1mM DTT, 1mM EDTA) pH 7.85 at 21°C to a concentration 663 
of 1mM as determined by UV absorbance (extinction coefficient of 8200 at 372 nm). This 664 
solution was mixed with a 20 mg/mL solution of P. pyralis (inhibitor:enzyme ratio of ~3:1) 665 
at room temperature and then incubated at 15 °C for 20 min. The inhibitor:enzyme solution 666 
was centrifuged and the supernatant was frozen in liquid nitrogen in ~ 18 - 50 µL aliquots 667 
and stored at -80 °C for future crystallisations. 668 
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 669 
Crystallizations used the hanging drop vapour diffusion method. Drops containing 1-2 µl of 670 
inhibitor:enzyme solution were mixed with the same volume of well solution and equilibrated 671 
against 500 µl of well solution, incubated at 4 °C, with crystals typically appearing within 48 672 
hours. Glycerol was used as a cryoprotectant, in an optimized well solution of 150 mM 673 
(NH4)2SO4, 50 mM HEPES pH 7.0, 2% PEG 1000.  674 
 675 
Data were collected at the Diamond Light Source on beam line IO4-1, at wavelength 676 
0.91587Å, and 100 K. Processing and data reduction were carried out on site using 677 
CrysalisPro (Agilent Technologies), and synchrotron data sets were processed and scaled by 678 
using XDS, SCALA and XIA2 programs. Molecular replacement methods were used 679 
successfully to determine the relative orientation and position of the two monomers in the 680 
asymmetric unit using the PHASER program 
29
. The starting dehydroinfraluciferin DLSA 681 
complex model was derived from the Firefly luciferase apo structure (PDB-ID 3IEP) with all 682 
solvent atoms and the luciferin removed. A simple rigid body refinement was sufficient to 683 
initiate refinement, with subsequent refinement and model building cycles performed using 684 
Refmac5 and Coot
  30,31
. 685 
 686 
Firefly luciferase mutants and cell lines 687 
FLuc mutants contained 11 pH and temperature stabilising mutations 688 
(F14R/L35Q/A105V/V182K/T214C/I232K/D234G/E354R/D357Y/S420T/F465R) 
21
. 689 
FLuc_green contained an additional 3 mutations (V241I/G246A/F250S), and FLuc_red has 690 
the red-shifting mutation S284T, as well as the mutation R354I which is required to maintain 691 
the red-shift in this stabilised FLuc backbone 
23
. All FLuc mutants were codon optimised for 692 
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mammalian expression and cloned into the MLV-based splicing gamma retroviral vector 693 
SFG. The Raji B lymphoma cell line used in all experiments was transduced to express a 694 
FLuc mutant, and subsequently flow-sorted for pure FLuc expressing populations using a co-695 
expressed marker gene. For tumour cell lines FLuc.IRES was upstream of the marker gene 696 
CD34 or dNGFR as indicated. For T cells FLuc.2A_peptide was upstream of the CAR CD19-697 
4G7_HL-CD8STK-41BBZ.  698 
 699 
Production of retroviral supernatant 700 
HEK-293T packaging cells were plated at a density of 200’000 cells/ml in 100mm tissue 701 
culture dish ~24 hours prior to transfection. Transfections were performed when cells were 702 
50-70% confluent. A bulk transfection mixture was prepared where 30μl GeneJuice® 703 
Transfection Reagent (Merck millipore) was added to 470μl of plain RPMI for each 704 
supernatant to be produced. Following a 5 minute incubation at room temperature, a total 705 
volume of 12.5μg of DNA was added for each plate to be transfected (for retroviral 706 
transfection: 3.125μg RDF RD114 env plasmid, 4.6875μg PeqPam-env gagpol plasmid, 707 
4.6875μg SFG retroviral construct). Following addition of plasmid DNA, the mixture was 708 
incubated for a further 15 minutes at room temperature prior to dropwise addition to the 709 
HEK- 293T cell culture. Plates were gently agitated following transfection. Supernatant 710 
harvested at 48 hours was stored at 4°C, and was then combined with the 72 hour harvest 711 
prior to aliquoting and storage at -80°C.  712 
 713 
Transduction of cell lines 714 
The day prior to transduction Raji B lymphoma cells (atcc
® 
ccl-86
™
) (>90% viable) were 715 
diluted ~1 in 10 to ensure exponential growth for transduction; also a well of non-tissue 716 
culture treated 24 well plate was coated with 8μg/ml retronectin (Lonza) for every plasmid to 717 
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be transduced and left at 4°C overnight. The next day retronectin was aspirated and 250μl of 718 
each retroviral supernatant for transduction was added to a well and incubated for 30 minutes 719 
at room temperature. Whilst incubating, Raji cells were harvested, counted and resuspended 720 
at a concentration of 600,000 cells/ml. supernatants were aspirated from wells of retronectin 721 
coated plate and 500μl of cell suspension was added to each well followed by 1.5ml of the 722 
same retroviral supernatant that was previously incubated in each well. Cells were spin 723 
transduced at 1000 RCF for 40 minutes then returned to incubator for 48 hours before harvest 724 
and expression testing. 725 
 726 
Flow cytometry and Fluorescence Activated Cell Sorting 727 
Transduction efficiencies were assessed by flow cytometry, based on marker gene expression 728 
as indicated by antibody staining using the BD LSR Fortessa™X-20. If necessary 729 
Fluorescence Activated Cell Sorting (FACS) was performed to obtain pure expressing 730 
populations, also based on marker gene expression as indicated by antibody staining, using 731 
the BD FACS Aria™ Fusion. FACS was also use to sort populations of cells expressing 732 
differing levels of FLuc_green and FLuc_red within the same cell. Concentration of antibody 733 
used was guided by manufacturer’s instructions. Anti-human CD34-PE (clone 581), anti-734 
human CD271-APC (clone ME20.4) and anti-mouse/human CD11B-PerCP/Cy5.5 (clone 735 
M1/70) (Biolegend). Anti-humanCD19-FITC (clone HIB19), anti-human CD20-eFluor450 736 
(clone 2H7) and Viability APC-eFluor780 (eBioscience). Data was analysed using Flow Jo 737 
software (Tree Star Inc, Oregon, USA). 738 
 739 
Flow cytometry of extracted bone marrow 740 
When bone marrow cells were required for flow cytometry analysis. Following animal 741 
sacrifice by CO2 narcosis and cervical dislocation, the femurs were removed and transferred 742 
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to PBS pending cellular harvest. The ends of the femur were snipped off using scissors and 743 
the bone was placed in an extraction tube (microfuge tube with holder made from 200μl 744 
pipette tip inserted). Tubes were centrifuged at 1000 RCF for 60 seconds. Bone marrow 745 
pellet was resuspended in 50μl Ammonium-Chloride-Potassium (ACK) lysing buffer (Lonza) 746 
and left for 60 seconds at room temperature before washing with PBS and passing through a 747 
70μm filter before pelleting. Samples were blocked 2.4G2 supernatant (rat anti-mouse CD32) 748 
supplemented with mouse Ig FcR blocking reagent (Miltenyl Biotec) for 30 minutes at room 749 
temperature. Cells were washed with PBS and pelleted, followed by each sample being 750 
transferred to a well of a U-bottomed 96 well plate before proceeding with antibody staining. 751 
An antibody master mix containing all antibodies to be used for staining was prepared in PBS 752 
to a total volume of 100μl per sample. Samples were left to stain at room temperature in the 753 
dark for 30 minutes. Samples were washed once with PBS, pelleted and transferred to FACS 754 
tubes. Beckman Coulter Flow-Check™fluorospheres were used as a stopping gate for flow 755 
cytometry analysis. Beads are supplied at 1x10e
6
 beads/ml in an aqueous solution containing 756 
preservative surfactant. To prevent toxicity to cellular samples, beads were washed once with 757 
PBS prior to addition to samples. Following centrifugation (400 RCF for 5 minutes), beads 758 
were resuspended in an equal volume of PBS with 10μl of beads added to each sample.  759 
 760 
As 6 fluorophores were used for bone marrow analysis, compensation was performed prior to 761 
sample acquisition using OneComp eBeads™ (eBioscience). Events were kept between 762 
2,000-5,000 events/second, with 1,000 events being recorded per sample, using flow check 763 
beads as a stopping gates (10% each sample). Flow cytometry gating first identified the 764 
lymphocyte population (FSC-A vs SSC-A), exclusion of doublet cells (SSC-A vs SSC-W); 765 
antibodies detailed in Flow cytometry and Fluorescence Activated Cell Sorting were then 766 
used to gate on viable cells, exclude mouse monocyte cells (mCD11b), identify the Raji 767 
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tumour cell population (CD19 and CD20) and finally co-expressed marker gene (dNGFR and 768 
dCD34). 769 
 770 
Preparation of CAR T cells 771 
On day 1 peripheral blood mononuclear cells were isolated from a healthy donor blood using 772 
Ficoll-paque density gradient media (GE  Healthcare). Cells were resuspended at 2x10
6 
/ml 773 
and stimulated with 1mg/ml PHA (Sigma). On day 2 cells were fed with IL-2 at a 774 
concentration of 100 U/ml (Genscript). On day 3 cells were transduced as described in 775 
transduction of cell lines, with IL-2 at a final concentration of 100 U/ml. On day 6 cells were 776 
harvested and resuspended at 1x10
6
/ml with 100 U/ml IL-2 and left to recover for at least 48 777 
hours before in vivo injection. Transduction efficiency was measured using flow cytometry. 778 
 779 
 780 
In vitro bioluminescence assays 781 
For spectrographic testing of FLuc, mutants were stably transduced in the mammalian Raji 782 
B-cell lymphoma cell line. For in vitro bioluminescence assays cells were harvested, counted 783 
and 1x106 cells/well were resuspended in TEM buffer (1M Tris-acetate, 20mM EDTA and 784 
100mM MgSO4 at pH 7.8) and added in triplicate to wells of a black 96-well plate 785 
(100μl/well). If mixtures of cells were used, total cell number remained the same. For 786 
spectral testing the stage temperature of the IVIS Spectrum was set to 37°C (automatic 787 
acquisition mode, FOV 13.2, f/1). iLH2 was synthesised by UCL Chemistry. Other substrates 788 
tested include D-luciferin (Regis Technologies), CycLuc1 (Merck Millipore) and Aka-789 
Lumine-HCL (Wako Pure Chemical Industries). Substrates were dispensed into the wells 790 
using a multi-channel pipette (at a final concentration of 300μM). A 2 minute delay was 791 
allowed for stabilisation of light output. Images were acquired through all 18 bandpass filters 792 
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on the IVIS Spectrum (20nm bandpass, 490nm to 840nm). Living image software (Perkin 793 
Elmer) was used for ROI analysis of spectral images and spectral unmixing analysis. Image 794 
analysis involved placing a ROI over the signal in each well. If a series of spectral images 795 
was acquired, the same ROI was placed over the well in every image for each plate. For 796 
spectral unmixing analysis, guided spectral unmixing was first used on pure expressing 797 
FLuc_green and FLuc_red populations to create a library spectra for each mutant with each 798 
substrate. The relevant library spectra was then used to perform spectral unmixing on mixed 799 
FLuc_green and FLuc_red populations (or cellular populations expressing both enzymes). 800 
Data exported to Excel (Microsoft) and Prism (Graphpad) for further analysis. Spectra was 801 
normalised to peak emission for each FLuc mutant with each substrate. Due to the 802 
characterisation nature of these in vitro experiments, and the substantial amounts of precious 803 
chemicals needed to synthesise iLH2, it was decided to repeat each in vitro experiment twice 804 
with 3 replicates 805 
 806 
In vivo models 807 
All animal studies were approved by the University College London Biological Services 808 
Ethical Review Committee and licensed under the UK Home Office regulations and the 809 
Guidance for the Operation of Animals (Scientific Procedures) Act 1986 (Home Office, 810 
London, United Kingdom). All of the in vivo models used the severely immunocompromised 811 
NSG (NOD.Cg PrkdcscidIl2rgtm1Wji/SzJ) mouse model (JAX™ mouse strain, Charles River). 812 
Mice were male and aged between 6-8 weeks old. Due to the characterisation, or proof of 813 
concept, nature of these experiments, and the substantial amounts of precious chemicals 814 
needed to synthesise iLH2, it was decided to engraft 4-5 mice for every condition in each 815 
model to ensure engraftment and survival in a least 3 animals for each condition. Also, no 816 
specific toxicity experiments were performed, but no adverse side effects were observed with 817 
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iLH2. 818 
For engraftment of subcutaneous tumours, FLuc expressing Raji cell lines were counted and 819 
2x106  cells were pelleted for each animal to be injected. Cells were washed twice in PBS 820 
before being resuspended in plain RPMI 1% HEPES (Sigma-Aldrich) to a concentration of 821 
2x107 cells/ml and were kept on ice ready for injection. Cells were injected subcutaneously 822 
(100μl bolus) into a shaved area of the flank. Mice were left at least 5 days for tumour 823 
development before imaging. 824 
 825 
For engraftment of systemic tumours, FLuc expressing Raji cell lines were counted and 5x105 826 
cells were pelleted for each animal. If mixtures of two different FLuc expressing cell lines 827 
were used, total cell number per mouse remained at 5x105 cells. Cells were washed twice in 828 
PBS before being resuspended in plain RPMI 1% HEPES to a concentration of 2.5x106 829 
cells/ml and were kept on ice ready for injection. Animals were transferred to a warming 830 
chamber set at 39-42°C to facilitate peripheral vasodilation prior to intravenous (IV) 831 
injections. Mice were placed in a restraint and cells were injected IV (200μl bolus) into the 832 
tail vein. Mice were left at least 7 days for tumour development before imaging. For the CAR 833 
T cell model 5x10
6 CAR positive T cells were injected IV (200μl bolus) 8 days after Raji cell 834 
engraftment. 835 
 836 
For engraftment of intracranial tumours, FLuc expressing Raji cell lines were counted and 837 
2x104 cells were pelleted for each animal. Cells were washed twice in PBS before being 838 
resuspended in PBS to a concentration of 1x104 cells/μl and were kept on ice ready for 839 
injection. Intracranial injections were performed using a stereotaxic frame fitted with a 840 
hamilton syringe. Cells were injected (2μl bolus) into the right striatum (from bregma 2 mm 841 
right, 1mm anterior, 4mm down). Mice were left at least 7 days for tumour development 842 
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before imaging. 843 
 844 
In vivo bioluminescence imaging  845 
For imaging of in vivo models, LH2 and iLH2 was solubilised in sterile PBS and animals 846 
were administered with substrate (2mg (or 100mg/kg) of either LH2 or iLH2 in 200μl or 400μl 847 
bolus respectively) via intraperitoneal (IP) injection. Animals were anaesthetised using 2% 848 
Isofluorine (flow rate 1 L/min O2). Spectral imaging was commenced 10 minutes post IP 849 
injection to allow stabilisation of light output. If the same animal was being imaged with both 850 
LH2 and iLH2, at least 24 hours was left between imaging to allow for full clearance of 851 
substrate. In vivo bioluminescent images were acquired using IVIS Spectrum (FOV 24, f/1, 852 
Medium (8)bin, automatic acquisition mode for imaging with LH2, FOV 24, f/1, Medium 853 
(8)bin, 120 s acquisition, total imaging time 24 mins for imaging with iLH2). These 854 
parameters are calculated to keep the binning, exposure time and f/stop within an optimal 855 
range for quantification. Up to 5 animals could be imaged at once and the stage was heated to 856 
37°C. Open filter images were acquired prior to and post spectral imaging to confirm the 857 
stability of photon emission during spectral acquisition. Spectral imaging acquired images 858 
through 14 and 12 of the 20nm bandpass filters on the IVIS Spectrum depending on substrate 859 
used (530-830nm for LH2 and 590-830nm for iLH2), starting from the lowest to the highest 860 
filter. It was not necessary to acquire images through all filters as the bioluminescent 861 
emissions of FLuc mutants did not cover the full spectral range from 490- 850nm. Living 862 
image software was used for ROI analysis of spectral images and spectral unmixing analysis. 863 
Radiance values for bioluminescence are shown using pseudo-colour scales detailed in each 864 
image. Image analysis involved placing an ROI over the tumour signal for every animal in 865 
each model. If a series if spectral images were acquired, the same ROI was placed over 866 
tumour signal in every image for each mouse. For spectral unmixing analysis, guided spectral 867 
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unmixing was first used on pure expressing FLuc_green and FLuc_red populations from 868 
spectral characterisation experiments to create a library spectra for each mutant with each 869 
substrate. The relevant library spectra was then used to perform spectral unmixing on mixed 870 
FLuc_green and FLuc_red populations. Data exported to Excel (Microsoft) and Prism 871 
(Graphpad) for further analysis  872 
 873 
Statistical analysis 874 
Where relevant means ± standard deviation of data given. Statistical tests used include T test 875 
and ONE-way ANOVA with post hoc Tukey’s test for multiple column comparison (Prism, 876 
Graphpad). Correlation analysis perform using Microsoft excel.  877 
ACKNOWLEDGMENTS 878 
 879 
We would like to thank Steven Pacman for the synthesis of infraluciferin, and the following 880 
masters students for their contributions to the synthesis of iDLSA, Laszlo Berencei (EPSRC 881 
vacation bursary) Boyuan Deng and Julia Holm (Erasmus), the MRC based at Imperial 882 
College London for the use of their IVIS Spectrum, especially to Dr Alex Sardini, and the 883 
core flow cytometry facility at UCL Cancer Institute for the sorting of cell lines. This work 884 
was partly funded by the National Science Foundation grant MCB-1410390, Force Office of 885 
Scientific Research grant FA9550-18-1-0017, Erba Diagnostics Mannheim and the EPSRC 886 
for an industrial CASE award EP/L504889/1 (SJP) and UCL. 887 
 888 
COMPETING INTERESTS 889 
The authors declare no competing interests. 890 
 891 
41 
 
 892 
FIGURE SUPPLEMENTS 893 
Figure 1 – figure supplement 1 data collection, phasing and refinement statistics for P. 894 
pyralis luciferase/dehydroinfraluciferin DLSA complex
 
 895 
Figure 1 – figure supplement 2 1H and 13C spectra for synthetic chemical compounds  896 
comparison of FLuc spectra with LH2 analogues in vitro 897 
Figure 2 – figure supplement 2 in vitro dual bioluminescence imaging within a single cell 898 
Figure 3 – figure supplement 1 bioluminescent images of FLuc mutants with infraluciferin in 899 
vivo 900 
Figure 3 – figure supplement 2 bioluminescent images of FLuc mutants with iluciferin in 901 
vivo 902 
Figure 5 – figure supplement 1 flow cytometry of extracted bone marrow samples 903 
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FIGURE 1 -FIGURE SUPPLEMENT 1 
Data collection and refinement statistics (molecular replacement) 
 
 Luciferase/iLH2  
Data collection  
Space group P 21 
Cell dimensions  
    a, b, c (Å) 47.509, 114.016, 101.557 
 ()  90.00, 98.18, 90.00 
Resolution (Å) 22.5- 3.1 (3.21) 
Rsym or Rmerge 22.7 (46.0) 
I / I 2.15 (1.1) 
Completeness (%) 94.2 (97.2) 
Redundancy 2.7 (2.6) 
  
Refinement  
Resolution (Å) 17.85 - 3.1 
No. reflections 17435(1328) 
Rwork / Rfree 27.4/32.0 (0.39/0.42) 
No. atoms  
    Protein 8428 
    Ligand/ion 84 
    Water 0 
B-factors - 
    Protein 43 
    Ligand/ion 24 
R.m.s. deviations - 
    Bond lengths (Å) 0.01 
    Bond angles () 1.417 
    
*Values in parentheses are for highest-resolution shell. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2 
 HJ2 HJ3 
Data collection   
Space group P 1 21 1 P 1 21 1 
Cell dimensions   
    a, b, c (Å) 48.3013, 45.9128, 62.4669 49.937, 45.374, 63.828 
 ()  90.00, 99.2863, 90.00  90.00, 101.01, 90.00 
Resolution (Å) 24-3.5 () * 49-2.69 (2.74-2.69) 
Rsym or Rmerge 10.5 () 5.4% (64%) 
I / I 17.4 () 10.9 (1.6) 
Completeness (%) 99.7 () 99.9 (97.6) 
Redundancy 6.1 () 3.6 (3.7) 
   
Refinement   
Resolution (Å) 30-3.05 49-3.0 
No. reflections 5038 5446 
Rwork / Rfree 23.0/32.3 24.6/28.5 
No. atoms   
    DNA 1684 1712 
    Ligand/ion 2 2 
B-factors   
    Protein 77 50 
    Ligand/ion  49 
R.m.s deviations   
    Bond lengths (Å) 0.008 0.008 
    Bond angles () 1.47 1.56 
*Values in parentheses are for highest-resolution shell. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3 
Data collection, phasing and refinement statistics for mad (semet) structures 
 Native  Crystal 1 
name 
  Crystal 2 
name 
 
Data collection        
Space group   common #   common #  
Cell dimensions        
    a, b, c (Å)   common #   common #  
 ()   common #   common #  
  Peak Inflection Remote Peak Inflection Remote 
Wavelength  # # # # # # 
Resolution (Å)  # # # # # # 
Rsym or Rmerge  # # # # # # 
I / I  # # # # # # 
Completeness (%)  # # # # # # 
Redundancy  # # # # # # 
        
Refinement        
Resolution (Å)   common  #   common #  
No. reflections        
Rwork / Rfree        
No. atoms        
    Protein        
    Ligand/ion        
    Water        
B-factors        
    Protein        
    Ligand/ion        
    Water        
R.m.s deviations        
    Bond lengths (Å)        
    Bond angles ()        
*Number of xtals for each structure should be noted in footnote. *Values in parentheses are for highest-
resolution shell.  
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FIGURE 1 - FIGURE SUPPLEMENT 2 1 
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